My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

7.100 +0.060 (+0.85%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023

August 01, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Ships One Millionth Gvoke® Unit

July 31, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

BioXcel Therapeutics, Alvotech And Other Big Stocks Moving Lower On Thursday ↗

June 29, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism

June 21, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Pharmaceuticals's Earnings Outlook ↗

March 07, 2023

Via Benzinga

Xeris Biopharma to Participate at the Jefferies Healthcare Conference

June 01, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma Reports First Quarter 2023 Financial Results

May 09, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023

May 02, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations

April 18, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Earnings Scheduled For May 9, 2023 ↗

May 09, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.

Via Benzinga

Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™

March 30, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma Appoints Ricki Fairley to Board of Directors

March 29, 2023

From Xeris Biopharma Holdings

Via Business Wire

Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance

March 08, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023

February 23, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023

February 02, 2023

From Xeris Biopharma, Inc.

Via Business Wire

Earnings Scheduled For March 8, 2023 ↗

March 08, 2023

Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.

Via Benzinga

Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®

January 30, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference

January 05, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma Updates Its Outlook For 2022

January 05, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Thursday ↗

January 05, 2023

On Thursday, 63 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

January 04, 2023

On Wednesday, 35 companies reached new 52-week lows.

Via Benzinga

Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism

December 15, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab

November 23, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma Reports Third Quarter 2022 Financial Results and Recent Events

November 09, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Earnings Scheduled For November 9, 2022 ↗

November 09, 2022

Companies Reporting Before The Bell • GCM Grosvenor (NASDAQ:GCMG) is likely to report quarterly earnings at $0.11 per share on revenue of $103.46 million.

Via Benzinga

Xeris Biopharma to Report Third Quarter 2022 Financial Results on November 9, 2022

November 02, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma Announces Results of the Extended Evaluation of Recorlev® (Levoketoconazole) From the Phase 3 Sonics Study Published in the European Journal of Endocrinology

November 01, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

10 Best Medical Stocks Under $5 ↗

October 29, 2022

The medical industry is one of the most lucrative sectors globally, and it is one that sees the highest spending in terms of research and development, and breakthrough advances through keeping up the...

Via Talk Markets

Xeris Biopharma Posts Encouraging Data From Reformulated Thyroid Hormone Deficiency Treatment In Healthy Participants ↗

October 20, 2022

Via Benzinga

Xeris Biopharma Announces Positive Topline Phase 1 Clinical Data of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121); Hosts Conference Call and Webcast

October 20, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.